News

The company will start evaluating new sources and distributors for the nutrients it needs to develop and distribute all-natural medicine formulas for treating specific wellness issues. NTRR CEO

Xarelto, an once-daily oral dosing anticoagulant, works by blocking the Xa blood clotting factor. The approval of Xarelto is backed by the pivotal double-blind Phase 3 ROCKET AF

Idera chairman and CEO Sudhir Agrawal said they have prioritized key areas for their internal investments following a thorough strategic review of their programs. "The proceeds of this

Humira, a TNF blocker used alone, with methotrexate, or with certain other medicines, will help prevent further damage to bones and joints. The randomised controlled Premier trial involved

The new clinical trial management system has key functionality to improve operations at sites and includes more automatic subject visit scheduling functionality and patient registry searches. The automated

Conducted by ORA, the trial demonstrated the safety and efficacy of the drug in a number of key Controlled Adverse Environment (CAE)-related parameters. The study, which did not

The double-blind, multicenter, placebo-controlled, randomized study is designed to assess the safety, tolerability, and efficacy of AVP-923. The primary efficacy endpoint will be measured based on the Numeric

As part of the agreement, Celgene, which will commit $45M to Quanticel during alliance term, will acquire an equity stake in Quanticel and will retain an option to

The rights include ATN-103 and PF-05230905 products. Ablynx will also acquire Pfizer intellectual property and know-how with regarding to the anti-TNF-alpha programmes and will have access to Pfizer’s